Risk factors
Vor Biopharma (VOR) risk factors
Item 1A of every Vor Biopharma Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors85 risks16 new28 dropped26 reworded
Vor Biopharma expanded its portfolio by in-licensing telitacicept from RemeGen, creating new operational and regulatory dependencies on third-party trials in China.
Filed Mar 30, 2026 - FY2024 10-K risk factors97 risks
Vor Biopharma faces significant net losses, an accumulated deficit of $457.0 million, and substantial doubt about its going concern status.
Filed Mar 20, 2025